Tetraphase Bets On I.V. Eravacycline Rerun As Antibiotic Market Influx Looms
Tetraphase has been keeping its head down since a 2015 Phase III trial failure for its lead antibiotic drug eravacycline sliced around $1.3bn from the company's market cap – but 2017 will be a turnaround year, says CEO Guy Macdonald.
You may also be interested in...
Promising drugs from Tetraphase, ContraFect, Spero and Entasis get a platform at the Infectious Diseases Society of America’s IDWeek.
Keeping Track: J&J Esketamine, Sanofi Caplacizumab Lead Off September Submissions; US FDA Says No To Nucala
The latest drug development news and highlights from our US FDA Performance Tracker.
Company presents game plan for targeting 1,900 high-prescribing hospitals in US in a launch kicking off in the second half of October.